We are live on ! Find out more
HBIO icon

Harvard Bioscience

74 hedge funds and large institutions have $80.6M invested in Harvard Bioscience in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,570% more call options, than puts

Call options by funds: $167K | Put options by funds: $10K

8% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 12

0% more funds holding

Funds holding: 7474 (0)

8% less capital invested

Capital invested by funds: $87.4M → $80.6M (-$6.87M)

13% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 24

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
74
Holders Change
Holders Change %
0%
% of All Funds
2.13%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
13
Increased
21
Reduced
24
Closed
12
Calls
$167K
Puts
$10K
Net Calls
+$157K
Net Calls Change
+$158K

HBIO Hedge Fund Activity: Q2 2014 in Review

74 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2014, worth a combined $80.6M — down 7.9% from $87.4M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new HBIO positions and 12 closed out — a net gain of 1 holder — while 21 added to existing stakes and 24 trimmed.

The largest buyer was Bank of Montreal, opening a new position worth an estimated $3.47M. The largest seller was Penbrook Management, cutting an estimated $2.85M.

  • 74 institutional investors held Harvard Bioscience (HBIO) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $80.6M of Harvard Bioscience stock for Q2 2014, down 7.9% quarter-over-quarter.
  • 13 funds opened new Harvard Bioscience positions in Q2 2014 and 12 closed out, a net change of +1 holder.
  • The largest Harvard Bioscience buyer in Q2 2014 was Bank of Montreal, an estimated $3.47M added.
  • The largest Harvard Bioscience seller in Q2 2014 was Penbrook Management, an estimated $2.85M sold.

Based on aggregated 13F filings for Q2 2014.